Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

BACKGROUND: Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide. Abrocitinib is a selective inhibitor of Janus kinase-1 (JAK1) enzyme inhibiting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadlalmola, Hammad Ali, Albadrani, Muayad Saud, Elhusein, Amal Mohamed, Mohamedsalih, Wahieba E., Swamy, Veerabhadra D. S., Mamanao, Daniel Mon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245258/
https://www.ncbi.nlm.nih.gov/pubmed/34257642
http://dx.doi.org/10.1155/2021/8382761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245258/
https://www.ncbi.nlm.nih.gov/pubmed/34257642
http://dx.doi.org/10.1155/2021/8382761

Ejemplares similares